Home/Pipeline/RVU120 (STING agonist)

RVU120 (STING agonist)

Advanced Solid Tumors

Phase IActiveNCT06072694

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase I

Status

Active

Company

Ryvu Therapeutics

About Ryvu Therapeutics

Ryvu Therapeutics is a Polish clinical-stage biotech focused on discovering and developing targeted small molecule therapies for cancer. Its strategy centers on tackling difficult-to-drug targets through a proprietary, integrated R&D platform, yielding a pipeline with both wholly-owned and partnered assets. Key achievements include advancing its lead program RVU120 into Phase I/II trials for hematological malignancies and securing a strategic partnership with BioNTech for its HPK1 inhibitor. The company aims to become a leader in precision oncology by translating novel biological insights into differentiated therapeutics.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
NST-101 (estimated)	Novastage Pharmaceuticals	Phase 1/2	Active
Meta10-TILs	Leman Biotech	Phase 1	Active (Investigator-Initiated Trial)
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
M8891	Merck KGaA	Phase 1/2	Active
P-002	Panacea Biotec	Phase 1/2	Active
Undisclosed kinase inhibitor	Tyligand Bioscience	Phase 1	Active
TYK-001	TYK Medicines	Phase 1/2	Active
PT-112	SciClone Pharmaceuticals	Phase 1	Active - Subject Recruitment
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion